Related Experiment Video
Updated: Mar 26, 2026
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells
Dain Park, In Jin Ha1, Sang-Yoon Park
1Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine Hospital , Seoul 02447, Republic of Korea.
Abstract:
Glioblastoma is one of the most malignant primary tumors, and the prognosis for glioblastoma patients remains poor. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) is considered a promising anticancer agent due to its remarkable ability to selectively kill tumor cells. However, since many cancers are resistant to TRAIL, strategies to overcome resistance are required for the successful use of TRAIL in the clinic. In the present study, the potential of morusin as a TRAIL sensitizer in human glioblastoma cells was evaluated. Treatment with TRAIL or morusin alone showed weak cytotoxicity in human glioblastoma cells. However, combination treatment of TRAIL with morusin synergistically decreased cell viability and increased apoptosis compared with single treatment. Morusin induced expression of death receptor 5 (DR5), but not DR4 or decoy receptors (DcR1 and DcR2). Furthermore, morusin significantly decreased anti-apoptotic molecules survivin and XIAP. In addition, morusin reduced expression of EGFR and PDFGR as well as phosphorylation of STAT3, possibly mediating down-regulation of survivin and XIAP. Together these results suggest that morusin enhances TRAIL sensitivity in human glioblastoma cells through regulating expression of DR5 and EGFR. Therefore, the combination treatment of TRAIL and morusin may be a new therapeutic strategy for malignant glioma patients.
Insights
Morusin enhances the effectiveness of Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL) therapy in glioblastoma. This combination treatment synergistically reduces cancer cell viability and promotes apoptosis, offering a potential new strategy for malignant glioma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Glioblastoma is a highly malignant brain tumor with a poor prognosis.
- Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL) shows selective tumor cell-killing potential but faces resistance.
- Strategies to overcome TRAIL resistance are crucial for its clinical application.
Purpose of the Study:
- To evaluate morusin as a sensitizer to TRAIL therapy in human glioblastoma cells.
- To investigate the molecular mechanisms by which morusin enhances TRAIL-induced apoptosis.
- To explore the potential of combining morusin and TRAIL as a novel therapeutic approach for glioblastoma.
Main Methods:
- Human glioblastoma cells were treated with TRAIL, morusin, or a combination.
- Cell viability and apoptosis were assessed.
- Expression levels of death receptors (DR5, DR4, DcR1, DcR2), anti-apoptotic molecules (survivin, XIAP), EGFR, and PDFGR were analyzed.
- STAT3 phosphorylation was measured.
Main Results:
- Combined TRAIL and morusin treatment synergistically decreased glioblastoma cell viability and increased apoptosis compared to single treatments.
- Morusin induced death receptor 5 (DR5) expression.
- Morusin decreased the expression of anti-apoptotic proteins survivin and XIAP.
- Morusin reduced EGFR and PDFGR expression and STAT3 phosphorylation.
Conclusions:
- Morusin acts as a TRAIL sensitizer in human glioblastoma cells.
- Morusin enhances TRAIL sensitivity by upregulating DR5 and downregulating EGFR.
- The combination of TRAIL and morusin represents a promising therapeutic strategy for malignant gliomas.
More Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
01:22PI3K/mTOR/AKT Signaling Pathway